ALSO NOTED: Dr. Reddy's raising $260M; Alexion wins priority review; new data supports orencia; and much more...

> The generic drug maker Dr. Reddy's Laboratories plans to raise $260 million through an issue of 13.5 million American Depositary Shares. The Indian company has been on an acquisition spree, acquiring Germany's Betapharm in March as it pursued a strategy of expanding in the European market. Report

> The FDA has agreed to provide a priority review of Alexion Pharmaceuticals' anemia drug eculizumab. Report

> Bristol-Myers Squibb is touting new data that shows orencia helped improve a form of arthritis in children. Report

> Regeneron Pharmaceuticals, which is researching new therapies for cancer and eye and inflammatory diseases, plans to offer 7.6 million common shares. Release

> Roche's Tamiflu will carry new warnings about delirium. Report

> Cancer diagnostic company Zila has signed agreements for a $40 million private placement. Release

> DeCODE genetics is proposing to make an offering of 3.5% senior convertible notes due 2011. Release

> Spectrum Pharmaceuticals announced that it has settled a patent dispute with Glaxo over a generic version of Imitrex injection. Report

> Huifeng Bio-Pharmaceutical announced today that it has agreed to purchase two production lines of a Chinese corporation in exchange for 2 million newly issued shares of Huifeng restricted stock. Release

And Finally… Researchers in Sweden provided free junk food to students to test the effects of a high-fat diet. They gained weight, but their bodies swiftly adjusted to the change. Article